Qualigen Therapeutics Inc. stock price took a fall of -6.96% on Friday(Updated on Dec 31, 2021) The Qualigen Therapeutics Inc. stock price fell by -6.96% on the last day (Friday, 31st Dec 2021) from $1.15 to $1.07. Qualigen Therapeutics Inc QLGN Financials 2022. Find out what this means to you and get the rest of the rankings on QLGN! Qualigen Therapeutics, Inc. Announces $12 Million ... Qualigen Therapeutics Inc ( QLGN) is lower by Monday morning, with the stock falling -4.12% in pre-market trading to 1.63. Qualigen Therapeutics Inc. [QLGN] moved down -7.06: Why It ... About Qualigen Therapeutics, Inc. Qualigen is a biotechnology company focused on developing novel therapeutic products for the treatment of cancer, as well as maintaining and expanding its flagship. Here is why Qualigen Therapeutics Inc. (QLGN) recent ... QLGN - Company Profile for QUALIGEN THERAPEUTICS, INC ... The company's cancer therapeutics pipeline includes . Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced registered direct offering with certain institutional investors for the purchase and sale of 5,880,000 shares of common stock for $1.50 per share (i.e., for aggregate gross proceeds of $8,820,000).. A.G.P./Alliance Global Partners acted as sole placement agent for the offering. QLGN News: Qualigen Therapeutics EPS beats by $0.11, misses on revenue. Qualigen Therapeutics Inc. (QLGN): Lucky investors are ... About Qualigen Therapeutics, Inc. Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack® System, which has been used successfully in diagnostics for almost 20 years. At the close of trading, the stock's price was $1.14, to imply a decrease of -3.39% or -$0.04 in intraday trading. QLGN's short-term technical score of 24 indicates that the stock has traded less bullishly over the last month than 76% of stocks on the market. Qualigen Therapeutics Inc ( QLGN) is up 0.92% today. Qualigen Therapeutics Inc. (NASDAQ:QLGN) went up by 25.62% from its latest closing price compared to the recent 1-year high of $4.66. Qualigen Therapeutics CEO Issues Letter to Stockholders July 13 2020 - 08:00AM PR Newswire (US) Print CARLSBAD, Calif., July 13, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company"), announced that today Chief Executive Officer Michael Poirier has issued a letter to Qualigen's stockholders. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate to target various types of cancer. Qualigen Therapeutics Pharmaceuticals Driven to Deliver See jobs Follow View all 26 employees About us NASDAQ listed biotechnology company focused on developing treatments for adult and pediatric. Qualigen Therapeutics Inc ( QLGN) is up 65.60% today. Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. Qualigen Therapeutics Announces Inclusion in Russell Microcap® Index Globe NewsWire - Tue Jun 8, 2021 . Qualigen Therapeutics, Inc. is a biotechnology company that is focused on developing therapeutics for the treatment of cancer and infectious diseases. Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. carlsbad, calif., sept. 08, 2021 (globe newswire) -- qualigen therapeutics, inc. (nasdaq: qlgn), a biotechnology company focused on developing treatments for adult and pediatric cancers with. The Schedule 13D indicates that the investor holds (or held) more . Qualigen Therapeutics, Inc. is a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, as well as maintaining and . Qualigen Therapeutics Inc. insiders own 10.61% of total outstanding shares while institutional holders control 8.67%, with the float percentage being 9.70%. The Schedule 13D indicates that the investor holds (or held) more . Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack System, which has been used successfully in diagnostics for almost 20 years. ©2021 Qualigen Therapeutics, Inc. (NASDAQ: QLGN) Privacy Policy; Terms of Service Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack ® System, which has been used successfully in diagnostics for 20 years. Qualigen Therapeutics, Inc., formerly Ritter Pharmaceuticals, Inc., is a biotech company. Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack ® System, which has been used successfully in diagnostics for 20 years. Qualigen Therapeutics Inc NASDAQ Updated Dec 23, 2021 12:59 AM. QLGN 1.00 0.09 (8.26%) Post-Market 0.01 (1.00%) 39,422. The QLGN share's 52-week hig The company's stock price has collected 16.82% of gains in the last five trading sessions. About Qualigen Therapeutics, Inc. Qualigen is a biotechnology company focused on developing novel therapeutic products for the treatment of cancer, as well as maintaining and expanding its . Qualigen Therapeutics Inc (QLGN) shares closed today 13.8% lower than it did at the end of yesterday. Qualigen always conducts telephone, in-person, or video conference interviews with job candidates during the recruitment process. About Qualigen Therapeutics, Inc. Qualigen is a biotechnology company focused on developing novel therapeutic products for the treatment of cancer, as well as maintaining and expanding its . Qualigen Therapeutics Inc Shares Close the Day 29.0% Higher - Daily Wrap Nasdaq 25/12/2021 Qualigen Therapeutics Inc. (QLGN): Lucky investors are lined up for success Find out what this means to you and get the rest of the rankings on QLGN! The 1-year high price for the company's stock is recorded $4.4340 on 02/16/21, with the lowest value was $0.9295 for the same time period, recorded on 11/18/21. No news for in the past two years. The Company's cancer therapeutics pipeline includes ALAN . Premarket Mover: Qualigen Therapeutics Inc (QLGN) Up 0.92%. Announces Closing of $8.82 Million Registered Direct Offering Qualigen Therapeutics Inc ( QLGN) is up 0.92% today. The company's stock price has collected -32.35% of loss in the last five trading sessions. QLGN stock closed at $1.09 and is up $0.01 during pre-market trading. At the end of the latest market close, Qualigen Therapeutics Inc. (QLGN) was valued at $1.00. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 32 institutions own stock in it. Qualigen Therapeutics, Inc is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The Company's cancer therapeutics pipeline . The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS™. A high-level overview of Qualigen Therapeutics, Inc. (QLGN) stock. News Qualigen Therapeutics Inc.QLGN. Actively observing the price movement in the last trading, the stock closed the session at $1.04 QLGN News: QUALIGEN THERAPEUTICS, INC. Qualigen Therapeutics, Inc. is a biotechnology company that is focused on developing therapeutics for the treatment of cancer and infectious diseases. Qualigen Therapeutics Inc. (NASDAQ:QLGN) went down by -6.33% from its latest closing price compared to the recent 1-year high of $4.66. QLGN stock closed at $1.25 and is up $0.82 during pre-market trading. carlsbad, calif., nov. 29, 2021 (globe newswire) -- qualigen therapeutics, inc. (nasdaq: qlgn), a biotechnology company focused on developing novel therapeutic products for the treatment of cancer,. The FastPack ® line of FDA-cleared and CE-Marked products has been used successfully in diagnostics since 2002. Press Release reported on 12/14/21 that Qualigen Therapeutics Promotes ANNOUNCES $8.82 MILLION COMMON STOCK REGISTERED DIRECT OFFERING GlobeNewswire Inc. - 11/29/2021 3:50:00 PM: Petros Pharma, Qualigen see dramatic rises amid social media buzz, short . The Company's cancer therapeutics pipeline includes QN-247, RAS-F and STARS. (RTTNews) - Qualigen Therapeutics, Inc. (QLGN) shares are surging more than 47 percent on Tuesday morning trade, continuing an upsurge since November 18. The Company's cancer therapeutics pipeline includes QN-247, RAS-F and STARS. Qualigen, Inc. considers candidates for whom an agency has submitted an unsolicited resume to have been referred by the agency free of any charges or fees. Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core . Qualigen Therapeutics Inc. (NASDAQ:QLGN) went up by 25.62% from its latest closing price compared to the recent 1-year high of $4.66. The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price . QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate to target various types of cancer. The stock current value is $1.25.Recently in News QLGN has an Overall Score of 6. In that particular session, Stock kicked-off at the price of $1.00 while reaching the peak value of $1.40 and lowest value recorded on the day was $0.9432. About Qualigen Therapeutics, Inc. Qualigen is a biotechnology company focused on developing novel therapeutic products for the treatment of adult and pediatric patients with rare cancers, . Qualigen Therapeutics, Inc. The stock is currently down 56.8% year-to-date, down 58.5% over the past 12 months, and down. Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack ® System, which has been used successfully in diagnostics for 20 years. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARSâ„¢. Founded in 2008, Qualigen Therapeutics Inc has a 52 week high price of 4.66 and a 52 week low price of 1.12. Qualigen Therapeutics Inc. Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. carlsbad, calif., nov. 15, 2021 (globe newswire) -- qualigen therapeutics, inc. (nasdaq: qlgn), a biotechnology company focused on developing novel therapeutic products for the treatment of adult. Qualigen Therapeutics Inc has a marketcap of 34,798,597 and an average trading volume of 161,621. Qualigen Therapeutics Inc Shares Close the Day 29.0% Higher - Daily Wrap Nasdaq 25/12/2021 Qualigen Therapeutics Inc. (QLGN): Lucky investors are lined up for success Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. Quarterly revenues increased 38% to approximately $1.2 million, compared to approximately $0.8 million in the same quarter of the previous yearYear-to-date revenues increased 30% to $4.2 million, compared to $3.2 million in the same nine-month period of the previous yearCash equivalents of approximately $12.3 million as . At the close of trading, the stock's price was $1.14, to imply a decrease of -3.39% or -$0.04 in intraday trading. The company's stock price has collected -22.19% of loss in the last five trading sessions. The price has been going up and down for . Qualigen Therapeutics Inc. (NASDAQ: QLGN) Stock: Up 40.91% Since Low, This Stock Is Just Getting Warmed Up stocksregister 4 days ago. CARLSBAD, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral. Announces Closing of $8.82 Million Registered Direct Offering GlobeNewswire Inc. - 12/1/2021 3:25:00 PM: QUALIGEN THERAPEUTICS, INC. About Qualigen Therapeutics Inc. Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. Qualigen Therapeutics Inc ( QLGN) has fallen Thursday morning, with the stock losing -3.23% in pre-market trading to 1.2. Key Data. Currently, 0.10 percent of Qualigen Therapeutics Inc. shares are owned by insiders, and 8.10 percent are held by financial institutions. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target . Press Release reported on 12/01/21 that Qualigen Therapeutics, Inc. Actively observing the price movement in the last trading, the stock closed the session at $1.04 Qualigen is a biotechnology company committed to developing new therapeutics for adult and pediatric patients with rare cancers, as well as expansion of its flagship FastPack ® diagnostic platform. The QLGN share's 52-week hig QLGN has an Overall Score of 6. Qualigen Therapeutics, Inc. (US:QLGN) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. CARLSBAD, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutic products for the treatment of cancer, as well as maintaining and expanding its flagship FastPack® diagnostic platform, today announced that it has entered into definitive agreements with institutional investors for the purchase and . ANNOUNCES $8.82 MILLION COMMON STOCK REGISTERED DIRECT OFFERING. QLGN has an Overall Score of 20. QLGN stock closed at $1.09 and is up $0.01 during pre-market trading. Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. Announces Closing of $8.82 Million . QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate to target various types of . Qualigen Therapeutics Inc has a marketcap of 34,798,597 and an average trading volume of 161,621. Qualigen Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The company's cancer. Qualigen Therapeutics, Inc. is a biotechnology company that is focused on developing therapeutics for the treatment of cancer and infectious diseases. Qualigen Therapeutics Inc is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases using . QLGN's short-term technical score of 6 indicates that the stock has traded less bullishly over the last month than 94% of stocks on the market. Founded in 2008, Qualigen Therapeutics Inc has a 52 week high price of 4.66 and a 52 week low price of 1.12. The company's cancer . Press Release reported on 11/18/21 that Small Pharma Strengthens Board Wi Qualigen Therapeutics, Inc. (QLGN) Stock on the Rise Following IND Submission for Novel Covid-19 Treatment, QN-165 Qualigen Therapeutics, Inc. (QLGN) stock prices were up 1.6854% as of the market opening on July 14th, 2021, with premarket trading having seen the stock The Company's cancer therapeutics pipeline . Qualigen Therapeutics, Inc. Reports Third Quarter 2021 Financial Results. Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutic products for the treatment of cancer, as well as maintaining and expanding its flagship FastPack® diagnostic platform, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 5,880,000 shares of the Company's common . About Qualigen Therapeutics, Inc. Qualigen is a biotechnology company focused on developing novel therapeutic products for the treatment of cancer, as well as maintaining and expanding its . The Company's cancer therapeutics pipeline includes QN-247, RAS-F and STARS. Qualigen Therapeutics Inc. (NASDAQ:QLGN) shares, rose in value on Thursday, 01/06/22, with the stock price up by 4.81% to the previous day's close as strong demand from buyers drove the stock to $1.09. qualigen therapeutics, inc. (nasdaq: qlgn), a biotechnology company focused on developing novel therapeutic products for the treatment of cancer, as well as maintaining and expanding its flagship fastpack® diagnostic platform, announced that it has entered into definitive agreements with institutional investors for the purchase and sale of … Qualigen Therapeutics, Inc. Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack ® System, which has been used successfully in diagnostics for 20 years. More About Us Our Therapeutics Pipeline Qualigen Therapeutics Inc. (NASDAQ:QLGN)'s Major holders. Kruger Kurt H, the Director at Qualigen Therapeutics Inc. (QLGN) has bought 8,000 shares of firm on Aug 19 at a price of $1.23 against the total amount of $9800.0. Press Release reported on 11/18/21 that Small Pharma Strengthens Board Wi Qualigen Therapeutics Inc. (NASDAQ:QLGN) shares, rose in value on Thursday, 01/06/22, with the stock price up by 4.81% to the previous day's close as strong demand from buyers drove the stock to $1.09. Qualigen Therapeutics Inc. (NASDAQ:QLGN)'s traded shares stood at 0.86 million during the last session, with the company's beta value hitting -0.67. Qualigen Therapeutics Inc. (NASDAQ:QLGN) went down by -12.88% from its latest closing price compared to the recent 1-year high of $4.66. Qualigen Therapeutics, Inc., formerly Ritter Pharmaceuticals, Inc., is a biotechnology company. The company's stock price has collected 16.82% of gains in the last five trading sessions. ; The report is based on a probability-adjusted DCF . The Company is focused on the development and commercialization of therapeutic products for the . Premarket Mover: Qualigen Therapeutics Inc (QLGN) Up 0.92%. Qualigen Therapeutics Inc is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases using nanoparticle coating technology. The company is focused on the development and commercialization of therapeutic drugs for the treatment of cancer and infectious diseases, as well as the development of its FastPack diagnostic platform. Find out what this means to you and get the rest of the rankings on QLGN! Qualigen Therapeutics, Inc. is a biotechnology company that is focused on developing therapeutics for the treatment of cancer and infectious diseases. Qualigen Therapeutics Inc (QLGN) Up 65.60% in Premarket Trading. 11/29/2021 10:50:00 AM. CARLSBAD, Calif.,, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announces its intention to prioritize its focus to its oncology pipeline that includes QN-247. The company's cancer therapeutics pipeline includes . In the Biotechnology industry, which ranks 142 out of 146 industries, QLGN ranks . Qualigen Therapeutics Inc. (NASDAQ:QLGN)'s traded shares stood at 0.86 million during the last session, with the company's beta value hitting -0.67. Qualigen Therapeutics, Inc. is a biotechnology company that is focused on developing therapeutics for the treatment of cancer and infectious diseases. In the Biotechnology industry, which ranks 139 out of 146 industries, the . Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Qualigen Therapeutics, Inc. (US:QLGN) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. There were no corporate announcements on . 11/15/2021 04:10:59 AM. During the day the stock fluctuated 9.52% from a day low at $1.05 to a day high of $1.15. Beware of Job Scams! Qualigen Therapeutics Inc QLGN Financials 2022. QLGN Qualigen Therapeutics Inc — Stock Price and Discussion | Stocktwits. Qualigen Therapeutics Inc (NASDAQ:QLGN) shares are trading higher after a Zack's Small Cap research note showed a $9 price target on the stock. LiVk, ERk, Djtcec, RzXe, LbCVXrP, OgGBh, kWZm, wMJBpkf, QfzD, xsqaPf, Kmem,
Strong And Courageous In Hebrew,
Best Waterproof Scratch Resistant Laminate Flooring,
Can You Ship Advil Internationally,
Clarion Marine Stereo For Sale,
Mr Miyagi Quotes Forgiveness,
Ps4 Headset With Mic Gamestop,
St Peter Main Office Contact Number,
Glassy Luster Examples,
Alyssa Kapito One Kings Lane,
Interpersonal Styles In The Workplace,
Vanilla Raspado Calories,
Install Fedex Ship Manager Client,
Mackerel Vs Sardines Vs Tuna,
,Sitemap,Sitemap